SARCLISA® (isatuximab) Update | Paul Richardson, MD | IMS 2022

REGN5458 Bispecific Antibody | Naresh Bumma, MD | IMS 2022

IMS Updates | Saad Usmani, MD, FACP | IMS 2022

What is induction therapy?

Fit Vs. Frail & Smoldering Myeloma | María-Victoria Mateos, MD, PhD | IMS 2022

Metabolomics | Rafael Fonseca, MD | IMS 2022

What AML mutations benefit from targeted therapy?

What is the difference between chemotherapy and targeted therapy?

What are the current treatment options available for patients with AML?

How likely is it that MDS will progress to AML? and how long does it usually take?

Do people who have their MDS turn into AML all have a certain type of AML? is AML due to MDS more or less severe than other types of AML?

(Guest Lecture): May 2022 - Translating Ideas Into Treatment - Dickran Kazandjian, MD

What are the signs, symptoms, and lab abnormalities of MDS?